Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company

B2i Digital, Inc. has announced that Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is now a Featured Company on its platform. This designation aims to bring the Sarasota, Florida-based clinical-stage biotechnology company's work to a broader audience of retail and institutional investors. The campaign will focus on Nu-3, a topical gel candidate for infected diabetic foot ulcers, and the Bisphosphocin class of antimicrobials.

The significance of this announcement lies in the urgent need for new antibiotics. Antimicrobial resistance (AMR) is a growing global health threat, with the World Health Organization (WHO) reporting that 830 million people live with diabetes, a third of whom will develop a diabetic foot ulcer. Approximately half of these ulcers become infected, and 15-20% of those infections involve resistant pathogens like MRSA. Lakewood-Amedex's Bisphosphocin compounds offer a novel mechanism of action, destabilizing bacterial cell membranes in a pH- and concentration-dependent manner, typically within one minute of exposure. This physical disruption is less prone to inducing resistance, as demonstrated in serial passage experiments where Nu-3 did not induce resistance.

Nu-3 is a topically delivered gel formulation designed to treat infected diabetic foot ulcers. The company is preparing a Phase 2a proof-of-concept study that will evaluate three concentrations: 2%, 5%, and 10%. The study chair is David G. Armstrong, DPM, M.D., Ph.D., a Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, who also serves as a Scientific Advisor for the program. Preclinical data reported in July showed that Nu-3 was well tolerated at dose levels substantially higher than those planned for Phase 2a, with very low systemic exposure and no inhibition of wound healing.

Lakewood-Amedex holds an intellectual property estate of 72 issued patents and 29 pending applications, covering composition of matter, formulations, use patents, and process patents, with principal filings running through 2038 and recent applications through 2044. The company began trading on the Nasdaq Capital Market under the symbol LABT following a direct listing in April 2026.

David Shapiro, CEO of B2i Digital, emphasized the importance of the company's science, stating, "Lakewood-Amedex has spent years on a compound class that disrupts the bacterial membrane physically, and in laboratory work Nu-3 has demonstrated a high barrier to resistance." Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex, added, "Working with B2i Digital gives us the opportunity to explain that science, and the milestones ahead of it, to a much broader group of investors than a company at our stage would normally reach."

The inclusion of Lakewood-Amedex in B2i Digital's Featured Companies program is a strategic move to highlight a promising candidate in the fight against antibiotic resistance. With the upcoming Phase 2a trial, the company is poised to generate proof-of-concept data that could define Nu-3's potential in a significant medical need. B2i Digital's extensive network, which includes 800+ news outlets and a combined monthly audience of 330 million, will amplify this message to investors and the broader healthcare community.